echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's new antifellar drug, Aishaconazole, has been declared on the market in China.

    Pfizer's new antifellar drug, Aishaconazole, has been declared on the market in China.

    • Last Update: 2020-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On July 4, Pfizer filed a CDE application in China for the listing of Essaconazole sulphuric acid capsules and injection aesulphate.
    , a new antifellar drug developed by Basilea Pharmaceutica, was approved by the FDA in March 2015 under the name Crisemba.
    Cresemba has been approved in more than 40 countries and territories around the world, with invasive creatosis and hairy mold, both of which can be life-threatening in patients with cancer or other immunodeficiability.
    December 2017, Pfizer reached an agreement with Basilea Pharmaceutica to obtain exclusive development and sales rights for Asaconzo in several countries in China and the Asia Pacific region.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.